Latest Kaiser Health News Stories
Under ordinary circumstances, these phases of vaccine development can take years to complete. But now, during the age of coronavirus, the timeline is being shortened. Here’s an inventory of where things stand.
A rule finalized this spring by the Trump administration permits employers and insurers not to apply drug company copayment assistance toward enrollees’ deductibles and out-of-pocket maximums for any drug.
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
KHN executive editor Damon Darlin wades through mounds of health care policy stories — so you don’t have to.
Sen. Kyrsten Sinema has received almost $100,000 from drug companies in the current election cycle, a KHN analysis shows, one of the largest cash hauls in Congress. And it’s only her first term.
A Kaiser Health News database tracks campaign donations from drugmakers over the past 10 years.
Trials are an immense undertaking involving tens of thousands of participants. They’re likely to start this summer — but don’t expect quick results. And what’s a successful result, anyway?
Vaccines and antivirals have long been an afterthought but Johnson & Johnson and other firms are widely publicizing how they might stop COVID 19.
Hay más de 1,250 estudios de COVID-19 en marcha. Las farmacéuticas están invirtiendo miles de millones en el desarrollo de medicamentos y vacunas eficaces para poner fin a la pandemia.
Thousands of researchers worldwide are looking for a treatment that will go beyond what remdesivir can do for COVID patients.
KHN’s Julie Rovner joins a panel of journalists on “1A” to talk about promising results in a study of the drug remdesivir and other developments in the battle against the coronavirus.
The Supreme Court this week, in an 8-1 decision, ruled that insurers are due the roughly $12 billion that Congress several years ago tried to cut off in payments under the Affordable Care Act’s “risk corridors” provision. And while the COVID-19 pandemic continues to rage in many places around the country, states are starting to reopen their economies at the urging of President Donald Trump and over objections of public health officials. Caitlin Owens of Axios and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss this and more. Also, Rovner interviews KHN’s Carmen Heredia Rodriguez, who wrote the latest KHN-NPR “Bill of the Month” installment about COVID testing that should have been free but was not.
Many Americans order drugs from Canada and other countries because they are cheaper, but U.S. authorities appear to be cracking down on the practice.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
The politics of COVID-19 are pretty polarized, but health experts across the ideological spectrum agree: The U.S. will need more robust testing before it’s safe to relax social-distancing requirements. Meanwhile, President Donald Trump, Congress and the nation’s governors continue to spar over who should be responsible for what. Kimberly Leonard of Business Insider, Tami Luhby of CNN and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
The proposal being weighed by federal officials would allow employers and insurers to decide that drug companies’ assistance doesn’t count toward their members’ deductible or out-of-pocket maximum spending limits. If plans opted for that approach, only payments made by patients themselves would be included in the calculation toward reaching those limits.
Josie and George Taylor of Everett, Washington, are two of the first people in the U.S. to recover from novel coronavirus infections after joining a clinical trial for the antiviral drug remdesivir.
Six states — Idaho, Louisiana, Nevada, North Carolina, Ohio and Texas — have taken steps to limit inappropriate prescriptions for the medicine and preserve supplies for patients who take it for lupus and rheumatoid arthritis.
Three senators on a revived subcommittee received more than $100,000 each from drugmakers.
Fifteen percent of hospital pharmacists who prepare injectable drugs are going without the protective masks they typically use or are using substitutes for masks.